Results of irradiation of inoperable stage III non-small cell lung cancer with 25 Gy in 5 fractions;Ergebnisse der bestrahlung inoperabler nichtkleinzelliger bronchialkarzinome im stadium III mit 25 Gy in funf fraktionen

Strahlentherapie und Onkologie

Volumn 175, Issue 6, 1999, Pages 267-270

  Appold, Steffen ^a   Baumann, Michael ^a,b   Neidt, Frauke ^a   Herrmann, Thomas ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Hypofractionated irradiation; Non small cell lung cancer; Palliative treatment

Indexed keywords

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PROGNOSIS; RADIATION DOSE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0033063597     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02743577     Document Type: Article

References (13)

1. Appold S, Baumann M, Petersen C, et ai. Comparison of the response of FaDu-squamous cell carcinoma in nude mice after hypofractionated-accelerated regimens and "curative" fractionation schedules. Strahlenther Onkol 1998;174:315-9.
2. Beck-Bornholdt HP, Dubben HH. Potential pitfalls in the use of p-values and in interpretation at the significant levels. Radiother Oncol 1994;33: 171-6.
3. Bleehen NM, Girling DJ, Payers PM, et al., on behalf of the Lung Cancer Working Party of the Medical Research Council. Inoperable non-small cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 1991;63:265-70.
4. Bleehen NM, Girling DJ, Machin D, et al., on behalf of the Medical Research Lung Cancer Working Party. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992;65:934-41.
5. Ginsberg RJ, Yokes EE, Raben A. Non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & practice of oncology, 5th edn. Philadelphia: Lippincott-Raven, 1997:858-911.
6. Hoskin P, Makin W. Oncology for palliative medicine. Oxford: Oxford University Press, 1998.
7. Ihde DC, Pfister DG, Baker S, et al. (ASCO non-small cell lung cancer expert panel). Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997;15:2996-3018.
8. Macbeth FR, Böiger JJ, Hopwood P, et al., on behalf of the Medical Research Council Lung Cancer Working Party. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol 1996;8:167-75.
9. Perez CA, Stanley K, Rubin P, et al. Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1980;6:987-94.
10. Saunders M, Dische S, Barre A, et al., on behalf of the CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomized multicentre trial. Lancet 1997;350:161-5.
11. Sause WT, Turrisi AT. Principles and application of preoperative and standard radiotherapy for regionally advanced non-small lung cancer. In: Pass HI, Mitchell JB, Johnson DU, et al. Lung cancer: Principles and practice. Philadelphia: Lippincott-Raven, 1996:697-710.
12. Stuschke M, Heilmann HP. Lunge und Mediastinum. In: Scherer E, Sack H, Hrsg. Strahlentherapie - Radiologische Onkologie, 4. Aufl. BerlinHeidelberg-New York: Springer, 1996:683-718.
13. Würschmidt F, Bünemann H, Bünemann C, et al. Inoperable non-small cell lung cancer: a retrospective analysis of 427 patients treated with high-dose radiotherapy. Int J Radiat Oncol Biol Phys 1994;28:583-8.